The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Johnson & Johnson (NYSE:JNJ) unit Janssen-Cilag International N.V.’s Ebola vaccine (MVA-BN-Filo [recombinant]), branded as Mvabea, for the prevention of Zaire ebolavirus disease.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3578594-european-advisory-group-backs-j-and-j-ebola-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.